The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer

Figures & data

Table 1 Clinicopathologic Characteristics Of All Patients

Variables	n	CRP/Alb<0.18	CRP/Alb≥0.18	p value
Patients (N)	595	392 (65.9%)	203 (34.1%)
Sex				0.062
Male	380	240 (61.2%)	140 (69.0%)
Female	215	152 (38.8%)	63 (31.0%)
Age (years)				0.249
≥65	233	147 (37.5%)	86 (42.4%)
<65	362	245 (62.5%)	117 (57.6%)
Location of tumor				0.025
Head	197	142 (36.2%)	55 (27.1%)
Body or tail	398	250 (63.8%)	148 (72.9%)
Tumor diameter (cm)				<0.001
<4	258	191 (48.7%)	67 (33.0%)
≥4	337	201 (51.3%)	136 (67.0%)
Tumor spread				<0.001
Locally advanced	388	226 (57.7%)	162 (79.8%)
Metastatic	207	166(42.3%)	41 (20.2%)
CA19-9 (U/mL)				0.151
<37	116	83 (21.2%)	33 (16.2%)
≥37	479	309 (78.8%)	170 (83.8%)

Abbreviation: CRP/Alb, C-reactive protein/albumin ratio.

Table 2 Univariate And Multivariate Analyses For The Overall Survival Of All Patients According To Baseline CRP/Alb

Variables	n	Univariate Analysis			Multivariate Analysis
HR	95% CI	p value	HR	95% CI	p value
Entire cohort	595
Age (years)
<65	233	1
≥65	362	1.034	0.857–1.248	0.724
Location of tumor
Body or tail	398	1
Head	197	1.009	0.832–1.224	0.928
Sex
Female	215	1			1
Male	380	1.139	0.942–1.379	0.180	1.114	0.920–1.350	0.268
Tumor diameter (cm)
<4	258	1			1
≥4	337	1.468	1.218–1.768	<0.001	1.276	1.054–1.544	0.012
Chemotherapy
Yes	485	1			1
No	110	1.562	1.246–1.958	<0.001	1.393	1.103–1.758	0.005
CA19-9 (U/mL)
<37	116	1			1
≥37	479	1.588	1.234–2.043	<0.001	1.593	1.236–2.053	<0.001
Tumor spread
Locally advanced	207	1			1
Metastatic	388	2.048	1.671–2.509	<0.001	1.829	1.488–2.249	<0.001
Baseline CRP/Alb
<0.18	392	1			1
≥0.18	203	2.237	1.849–2.706	<0.001	1.840	1.510–2.242	<0.001

Abbreviations: HR, hazard ratio; CRP/Alb, C-reactive protein/albumin ratio.

Figure 1 Kaplan-Meier analysis of OS according to baseline CRP/Alb in all patients (A), in the locally advanced (B) and metastatic cohorts (C).

Table 3 Univariate And Multivariate Analyses For The Overall Survival Of Patients According To Baseline And Postchemotherapy CRP/Alb

Variables	n	Univariate Analysis			Multivariate Analysis
HR	95% CI	p value	HR	95% CI	p value
Entire cohort	213
Age (years)
<65	142	1
≥65	71	1.087	0.756–1.563	0.653
Location of tumor
Body or tail	137	1
Head	76	1.006	0.716–1.413	0.972
Sex
Female	73	1			1
Male	140	1.339	0.940–1.907	0.105	1.207	0.842–1.731	0.306
Tumor diameter (cm)
<4	102	1			1
≥4	111	1.273	0.916–1.769	0.150	1.072	0.76–1.513	0.691
CA19-9 (U/mL)
<37	47	1			1
≥37	166	1.373	0.902–2.090	0.139	1.486	0.971–2.275	0.068
Tumor spread
Locally advanced	80	1			1
Metastatic	133	2.140	1.492–3.609	<0.001	1.926	1.330–2.790	0.001
CRP/Alb
Baseline <0.18 Postchemotherapy <0.18	135	1			1
Baseline ≥0.18 Postchemotherapy <0.18	17	1.582	0.861–2.908	0.140	1.356	0.725–2.536	0.341
Baseline <0.18 Postchemotherapy ≥0.18	29	2.272	1.447–3.568	<0.001	2.158	1.355–3.437	0.001
Baseline≥0.18 Postchemotherapy ≥0.18	32	3.639	2.310–5.732	<0.001	3.132	1.952–5.025	<0.001

Note: Two hundred and thirteen patients had postchemotherapy CRP/Alb ratio data after two cycles of chemotherapy.

Abbreviations: HR, hazard ratio; CRP/Alb C-reactive protein/albumin ratio.

Figure 2 (A) Kaplan-Meier analysis of OS in patients after two cycles of chemotherapy according to postchemotherapy CRP/Alb. (B) OS of the patients after two cycles of chemotherapy according to baseline and postchemotherapy CRP/Alb.